A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

British Journal of Cancer

Volumn 111, Issue 4, 2014, Pages 660-666

  Kang, Y K ^a   Rha, S Y ^b   Tassone, P ^c   Barriuso, J ^d   Yu, R ^e   Szado, T ^e   Garg, A ^e   Bang, Y J ^f  

^a University of Ulsan College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e GENENTECH INC   (United States)

^f Seoul National University College of Medicine   (South Korea)

Author keywords

advanced gastric cancer; HER2; pertuzumab; pharmacokinetics; trastuzumab

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; TRASTUZUMAB;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LUNG EMBOLISM; LUNG MYCOSIS; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; STOMACH OBSTRUCTION; STOMATITIS; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DIARRHEA; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84906092045     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.356     Document Type: Article

References (47)

1. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23: 2534-2543.
2. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127-137.
3. Albanell J, Montagut C, Jones ET, Pronk L, Mellado B, Beech J, Gascon P, Zugmaier G, Brewster M, Saunders MP, Valle JW (2008) A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin Cancer Res 14: 2726-2731.
4. Attard G, Kitzen J, Blagden SP, Fong PC, Pronk LC, Zhi J, Zugmaier G, Verweij J, de Bono JS, de Jonge M (2007) A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer 97: 1338-1343.
5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
6. Bang Y-J, Xu R, Satoh T, Yeh K-H, Katsura K, Yoshida P, Mukaiyama A, Kobayashi M, Ohtsu A (2013) A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. J Clin Oncol 31(February 1 suppl): Abstr 11.
7. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. CLEOPATRA Study Group (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366: 109-119.
8. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138-1144.
9. Bruno R, Washington CB, Lu J, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2 metastatic breast cancer. Cancer Chemother Pharmacol 56: 361-369.
10. Chiba K, Yoshitsugu H, Kyosaka Y, Iida S, Yoneyama K, Tanigawa T, Fukushima T, Hiraoka M (2014) A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: are Japanese phase I studies still needed? J Clin Pharmacol 54: 483-494.
11. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760.
12. Cortés J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, Baselga J (2012) Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30: 1594-1600.
13. Cosson VF, Ng VW, Lehle M, Lum BL (2014) Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol 73: 737-747.
14. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R (2014) Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 15: 23-34.
15. De Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J (2007) Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 25: 257-262.
16. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM (2005) Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 241: 27.
17. Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49: 633-659.
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
19. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
20. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5: 317-328.
21. Gianni L, Llado A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, Hersberger V, Baselga J (2010) Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 1131-1137.
22. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13: 25-32.
23. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY (2006) Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24: 4324-4332.
24. Gupta M, LoRusso PM, Wang B, Yi J, Burris 3rd HA, Beeram M, Modi S, Chu Y, Agresta S, Klencke B (2012) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol 52: 691-703.
25. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds) (2011) SEER Cancer Statistics Review 1975-2008. National Cancer Institute: Bethesda, MD, USA. http://seer.cancer.gov/csr/1975-2008/(based on November 2010 SEER data submission, posted to the SEER web site).
26. Hecht JR, Bang Y, Qin S, Chung H, Xu J, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero AF, Salman P, Li J, Protsenko S, Buyse ME, Afenjar K, Kaneko T, Kemner A, Santillana S, Press MF, Slamon DJ (2013) Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. J Clin Oncol 31(June 20 suppl): LBA4001.
27. Herceptin Summary of Product Characteristics (2013). Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000278/WC500074922.pdf.
28. Hoff P, Tabernero J, Shen L, Ohtsu A, Yu R, Szado T, Kang Y (2013) Pertuzumab, trastuzumab and chemotherapy in HER2-positive metastatic gastric or gastro-oesophageal junction cancer: an international phase III study (JACOB). Ann Oncol 24(suppl 4): iv67.
29. Jackson C, Cunningham D, Oliveira J (2009) Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(suppl 4): 34-36.
30. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS (2013a) Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 45: 1-14.
31. Jung KW, Won Y, Kong H, Oh C, Shin A, Lee J (2013b) Survival of Korean adult cancer patients by stage at diagnosis, 2006-2010: National Cancer Registry Study. Cancer Res Treat 45: 162-171.
32. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15: 429-440.
33. Lordick F, Bang Y, Kang Y, Otero Reyes D, Manikhas G, Shen L, Kulikov E, Stoss O, Jordan B, Van Cutsem E (2007) HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. Eur J Cancer 5: 272 (abstract 3541).
34. Malik MA, Totpal K, Balter I, Sliwkowski MX, Pelletier N, Reich M, Crocker L, Friess T, Bauer S, Fiebig HH, Allison DE (2003) Dose response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models. Proc Am Assoc Cancer Res 44: 150.
35. Matsuda T, Saika K (2013) The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan. Jpn J Clin Oncol 43: 1157-1158.
36. Nahta R, Hung M, Esteva FJ (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64: 2343-2346.
37. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69: 9330-9336.
38. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai Y-, Ratnayake J, McNally V, Ross G, Cortés J (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline- containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24: 2278-2284.
39. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire W (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene. Science 235: 177-182.
40. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
41. Swain SM, Kim S, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013) Pertuzumab, trastuzumab and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14: 461-471.
42. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278.
43. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909.
44. Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K (2011) Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 17: 5060-5070.
45. Yang J, Zhao H, Garnett C, Rahman A, Gobburu JV, Pierce W, Schechter G, Summers J, Keegan P, Booth B, Wang Y (2013) The combination of exposure-response and case-control analyses in regulatory decision making. J Clin Pharmacol 53: 160-166.
46. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, Huang J (2009) Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 33: 2112-2118.
47. Zhu M, Doshi S, Gisleskog PO, Oliner KS, Perez Ruixo JJ, Loh E, Zhang Y (2014) Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients. J Pharm Sci 103: 328-336.